Zacks Investment Research downgraded GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) to Hold in a statement released earlier today.
- Updated: November 29, 2016
Yesterday GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) traded 0.12% higher at $117.93. GW Pharmaceuticals PLC- ADR’s 50-day moving average is $122.43 and its two hundred day average is $101.77. With the last close up 15.16% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.03% over the date range. Volume of trade was down over the average, with 307,833 shares of GWPH changing hands under the typical 707,295
Zacks Investment Research has downgraded GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) to Hold in a report released on 11/29/2016.
Recent Performance Chart
With a total market value of $0, GW Pharmaceuticals PLC- ADR has 52 week low of $35.83 and a 52 week high of $137.88 .
A total of 8 brokers have released a report on GW Pharmaceuticals PLC- ADR. Two brokerages rating the stock a strong buy, 5 brokerages rating the stock a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero firms rating the stock a sell with a consensus target price of $139.75.
About GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)
GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies. The Company operates through three segments: Commercial, Sativex Research and Development (Sativex R&D), and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex R&D segment seeks to maximize the potential of Sativex through the development of indications. The Sativex R&D segment focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using the Company's cannabinoid technology platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.